<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04050111</url>
  </required_header>
  <id_info>
    <org_study_id>SM-001</org_study_id>
    <nct_id>NCT04050111</nct_id>
  </id_info>
  <brief_title>The Evaluation of Safety and Effectiveness of Intraarticular Administration of Autologous Stromal-Vascular Fraction of Adipose Tissue Cells for Treatment of Knee Joint Arthrosis</brief_title>
  <official_title>The Evaluation of Safety and Effectiveness of Intraarticular Administration of Autologous Stromal-Vascular Fraction of Adipose Tissue Cells for Treatment of Knee Joint Arthrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Medica XXI Century S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Medica XXI Century S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stromal vascular fraction of cells (SVF) will be extracted from lipoaspirate by enzymatic&#xD;
      digestion. SVF will be administered in a single dose intraarticularly. All patients will&#xD;
      receive cell therapy.This is a single arm study with no control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with knee osteoarthritis will be subjected to abdominal liposuction under local&#xD;
      anaesthesia. Harvested adipose tissue will be processed according to patent pending&#xD;
      technology based on enzymatic digestion, washing and concentration of cell pellet in 5 ml of&#xD;
      Hartmann's solution. Isolated SVF will be administered in a single dose into anterior part of&#xD;
      knee joint cavity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">August 21, 2019</start_date>
  <completion_date type="Anticipated">August 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 22, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious adverse events (SAEs)</measure>
    <time_frame>4 weeks after treatment</time_frame>
    <description>Types, probability and severity of treatment emergent SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse reactions (SARs)</measure>
    <time_frame>4 weeks after treatment</time_frame>
    <description>Types, probability and severity of treatment emergent SARs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life monitoring-1</measure>
    <time_frame>Follow up to completion (up to 24 weeks after treatment)</time_frame>
    <description>Quality of life estimated by validated questionnaire - the Short Form (36) Health Survey (SF-36).&#xD;
SF-36 is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.&#xD;
The eight sections are:&#xD;
vitality&#xD;
physical functioning&#xD;
bodily pain&#xD;
general health perceptions&#xD;
physical role functioning&#xD;
emotional role functioning&#xD;
social role functioning&#xD;
mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life monitoring-2</measure>
    <time_frame>Follow up to completion (up to 24 weeks after treatment)</time_frame>
    <description>Quality of life estimated by validated questionnaire - Knee Injury and Osteoarthritis Outcome Score (KOOS).&#xD;
The KOOS is a patient reported joint-specific score, which assesses:&#xD;
patient pain (9 items),&#xD;
other symptoms (7 items),&#xD;
function in daily living (17 items),&#xD;
function in sport and recreation (5 items),&#xD;
knee related quality of life (4 items).&#xD;
Scores range from 0 to 100 with a score of 0 indicating the worst possible knee symptoms and 100 indicating no knee symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee pain intensity monitoring</measure>
    <time_frame>Follow up to completion (up to 24 weeks after treatment)</time_frame>
    <description>Knee pain intensity assessed by Visual Analog Pain Scale (no pain=0; maximum pain=100 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in knee joint structure-1</measure>
    <time_frame>Follow up to completion (up to 24 weeks after treatment)</time_frame>
    <description>Changes in knee joint structure assessed by ultrasonography (effusion, synovial thickening or hypertrophy, cartilage parameters, vascularity, Baker's cysts, osteophytes, tendon and ligament abnormalities, meniscal changes, bursitis, erosions and panniculitis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in knee joint structure-2</measure>
    <time_frame>Follow up to completion (up to 24 weeks after treatment)</time_frame>
    <description>Changes in knee joint structure assessed by X-ray (joint space width, bone contour, presence of osteophytes and sclerosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in knee joint structure-3</measure>
    <time_frame>Follow up to completion (up to 24 weeks after treatment)</time_frame>
    <description>Changes in knee joint structure assessed by MRI (articular cartilage, osteophytes, bone marrow abnormality, meniscal integrity, synovial effusion/tissue, anterior and posterior cruciate ligaments, and medial and lateral collateral ligaments)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in knee function</measure>
    <time_frame>Follow up to completion (up to 24 weeks after treatment)</time_frame>
    <description>Changes in knee function assessed by validated questionnaire: Knee Society Score (KSS).&#xD;
KSS consists of 4 separate sub-scales:&#xD;
&quot;Objective&quot; Knee Score (seven items: 100 points),&#xD;
Patient Satisfaction Score (five items: 40 points),&#xD;
Patient Expectation Score (three items: 15 points),&#xD;
Functional Activity Score (19 items: 100 points).&#xD;
Lower scores being indicative of worse knee conditions and higher scores being indicative of better knee conditions.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>SVF injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate stromal vascular fraction of cells (SVF). After SVF isolation autologous cells suspension will be injected intraarticularly into knee joint.&#xD;
Interventions:&#xD;
Procedure: Liposuction Other: SVF isolation Other: Intraarticular administration of autologous SVF</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stromal-vascular fraction</intervention_name>
    <description>Concentrate of stromal-vascular fraction of cells derived from autologous adipose tissue</description>
    <arm_group_label>SVF injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pain in the knee joint during more than a half day assessed by Visual Analog Pain&#xD;
             Scale (score more than 40 mm)&#xD;
&#xD;
          -  At least three of the following 6 criteria: 20-85 years of age, stiffness lasting less&#xD;
             than 30 minutes, crepitus, bony tenderness, bony enlargement, no warmth to the touch&#xD;
&#xD;
          -  Patient is able to walk without assistance&#xD;
&#xD;
          -  Patient is familiar with Participant information sheet&#xD;
&#xD;
          -  Patient signed informed consent form&#xD;
&#xD;
        Non-inclusion Criteria:&#xD;
&#xD;
          -  Medical history of endoprosthetic knee replacement&#xD;
&#xD;
          -  Medical history of lower extremity osteotomy&#xD;
&#xD;
          -  Medical history of knee surgery (including arthroscopy) during preceding 1 year prior&#xD;
             to enrollment&#xD;
&#xD;
          -  Medical history of intraarticular injections during preceding 6 months prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Secondary osteoarthritis of the knee joint: posttraumatic osteoarthritis (developed&#xD;
             after clinically significant injury), intra-articular fractures, clinically&#xD;
             significant varus or valgus deformities of lower limbs, septic arthritis, joint's&#xD;
             inflammatory disorders, gout, advanced chondrocalcinosis, Paget's disease, ochronosis,&#xD;
             acromegaly, hemochromatosis, Wilson's disease, primary synovial osteochondromatosis,&#xD;
             osteonecrosis, hemophilia&#xD;
&#xD;
          -  Patients prescribed for immunosuppressive treatment&#xD;
&#xD;
          -  Medical history of systemic autoimmune and inflammatory diseases&#xD;
&#xD;
          -  Significant weight loss (&gt; 10% of body weight in the previous year) of unknown&#xD;
             etiology&#xD;
&#xD;
          -  Medical history of venous thromboembolism or estimated high risk of venous&#xD;
             thromboembolism&#xD;
&#xD;
          -  Patients prescribed for systemic corticosteroids or other medications treatment with&#xD;
             proven impact on bone or cartilage tissue metabolism&#xD;
&#xD;
          -  Clinically significant abnormalities in results of laboratory tests&#xD;
&#xD;
          -  Any conditions limiting compliance (dementia, neuropsychiatric disease, drug and&#xD;
             alcohol abuse etc.)&#xD;
&#xD;
          -  Participation in other clinical trials (or administration of investigational drugs)&#xD;
             during 3 months prior inclusion&#xD;
&#xD;
          -  Patients with malignant tumors including postoperative period, patients receiving&#xD;
             chemotherapy and/or radiotherapy.&#xD;
&#xD;
          -  Patient's activated partial thromboplastin time exceeds normal levels more than 1,8&#xD;
             times&#xD;
&#xD;
          -  Patients prescribed for anticoagulants treatment or patient received anticoagulants at&#xD;
             least one hour prior liposuction&#xD;
&#xD;
          -  Medical history of heterotopic ossifications&#xD;
&#xD;
          -  Patients prescribed for glycoprotein inhibitors treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient's refusal from the further participation in trial&#xD;
&#xD;
          -  Patient's refusal from compliance with the requirements of contraception during the&#xD;
             participation in research&#xD;
&#xD;
          -  Chronic kidney disease IV- V stages (creatinine clearance &lt; 30 mL/min estimated by&#xD;
             Cockcroft-Gault formula)&#xD;
&#xD;
          -  Confirmed syphilis, HIV, hepatitis B or C infections&#xD;
&#xD;
        Dropout Criteria:&#xD;
&#xD;
        - Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey L Mikheev, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Swiss Medica XXI Century S.A.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ilya I Eremin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief scientific officer of Swiss Medica XXI Century S.A.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sergey L Mikheev, MD, PhD</last_name>
    <phone>+7-495-6180116</phone>
    <email>mikheev@swissmedica21.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ilya I Eremin</last_name>
    <phone>+7-495-6180116</phone>
    <email>ieremin@swissmedica21.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Swiss Medica XXI Century S.A.</name>
      <address>
        <city>Moscow</city>
        <zip>127521</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <last_name>Sergey L Mikheev, MD, PhD</last_name>
      <phone>+7-495-6180116</phone>
      <email>mikheev@swissmedica21.com</email>
    </contact>
    <contact_backup>
      <last_name>Ilya I Eremin, MD, PhD</last_name>
      <phone>+7-495-6180116</phone>
      <email>ieremin@swissmedica21.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IM Clinic</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <contact>
      <last_name>Igor Bolbukh, MD</last_name>
      <phone>+38162256891</phone>
      <email>doctor_bol@mail.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>Serbia</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 7, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SVF</keyword>
  <keyword>stromal-vascular fraction</keyword>
  <keyword>Stem cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

